Risk, management of VTE in bevacizumab-treated colorectal cancer

the ONA take:

Risk of venous thromboembolisms (VTEs) in patients with cancer can be high, according to researchers in British Columbia, Canada. This patient population is already predisposed to prothrombotic states.

The researchers assessed the incidence of VTEs in a cohort of patients with metastatic colorectal cancer (mCRC) who were treated with bevacizumab.

Using a cohort of 499 evaluable patients, the researchers found 81 patients developed VTEs after receiving bevacizumab, and nine patients experienced more than one event. Those patients who experienced VTEs were more likely to have pre-existing cardiovascular diseases, resection of the primary cancer, high pre-chemotherapy platelet count, and received more than 12 bevacizumab cycles. 

The researchers conclude the risk of VTEs can be high in patients receiving bevacizumab, especially in those with specific pretreatment risk factors and in those who received more of the drug.

Risk, management of VTE in bevacizumab-treated colorectal cancer
Researchers assessed the incidence of VTEs in a cohort of patients with metastatic colorectal cancer (mCRC) who were treated with bevacizumab.
We aimed to characterize the incidence of VTEs in a population-based cohort of mCRC patients treated with bevacizumab, describe patient and treatment factors associated with VTEs, and examine how VTEs are managed.
READ FULL ARTICLE From Springer
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs